• Brynjar O Jensson, Gudny A Arnadottir, Hildigunnur Katrinardottir, Run Fridriksdottir, Hannes Helgason, Asmundur Oddsson, Gardar Sveinbjornsson, Hannes P Eggertsson, Gisli H Halldorsson, Bjarni A Atlason, Hakon Jonsson, Gudjon R Oskarsson, Arni Sturluson, Sigurjon A Gudjonsson, Gudmundur A Thorisson, Florian Zink, Kristjan H S Moore, Gunnar Palsson, Asgeir Sigurdsson, Adalbjorg Jonasdottir, Aslaug Jonasdottir, Magnus K Magnusson, Anna Helgadottir, Valgerdur Steinthorsdottir, Julius Gudmundsson, Simon N Stacey, Rafn Hilmarsson, Isleifur Olafsson, Oskar T Johannsson, David O Arnar, Jona Saemundsdottir, Olafur T Magnusson, Gisli Masson, Bjarni V Halldorsson, Agnar Helgason, Hreinn Stefansson, Ingileif Jonsdottir, Hilma Holm, Thorunn Rafnar, Unnur Thorsteinsdottir, Daniel F Gudbjartsson, Kari Stefansson, and Patrick Sulem.
• From deCODE Genetics-Amgen (B.O.J., G.A.A., H.K., R.F., H. Helgason, A.O., G.S., H.P.E., G.H.H., B.A.A., H.J., G.R.O., A. Sturluson, S.A.G., G.A.T., F.Z., K.H.S.M., G.P., A. Sigurdsson, Adalbjorg Jonasdottir, Aslaug Jonasdottir, M.K.M., A. Helgadottir, V.S., J.G., S.N.S., D.O.A., J.S., O.T.M., G.M., B.V.H., A. Helgason, H.S., I.J., H. Holm, T.R., U.T., D.F.G., K.S., P.S.), the Faculty of Medicine, School of Health Sciences (G.A.A., M.K.M., R.H., D.O.A., I.J., U.T., K.S.), the Department of Anthropology (K.H.S.M., A. Helgason), and the School of Engineering and Natural Sciences (H. Helgason, G.H.H., D.F.G.), University of Iceland, the Departments of Urology (R.H.), Clinical Biochemistry (I.O.), Oncology (O.T.J.), Medicine (D.O.A.), and Immunology (I.J.), Landspitali-the National University Hospital of Iceland, and the School of Science and Engineering, Reykjavik University (B.V.H.) - all in Reykjavik, Iceland.
• N. Engl. J. Med. 2023 Nov 9; 389 (19): 174117521741-1752.

BackgroundIn 2021, the American College of Medical Genetics and Genomics (ACMG) recommended reporting actionable genotypes in 73 genes associated with diseases for which preventive or therapeutic measures are available. Evaluations of the association of actionable genotypes in these genes with life span are currently lacking.MethodsWe assessed the prevalence of coding and splice variants in genes on the ACMG Secondary Findings, version 3.0 (ACMG SF v3.0), list in the genomes of 57,933 Icelanders. We assigned pathogenicity to all reviewed variants using reported evidence in the ClinVar database, the frequency of variants, and their associations with disease to create a manually curated set of actionable genotypes (variants). We assessed the relationship between these genotypes and life span and further examined the specific causes of death among carriers.ResultsThrough manual curation of 4405 sequence variants in the ACMG SF v3.0 genes, we identified 235 actionable genotypes in 53 genes. Of the 57,933 participants, 2306 (4.0%) carried at least one actionable genotype. We found shorter median survival among persons carrying actionable genotypes than among noncarriers. Specifically, we found that carrying an actionable genotype in a cancer gene was associated with survival that was 3 years shorter than that among noncarriers, with causes of death among carriers attributed primarily to cancer-related conditions. Furthermore, we found evidence of association between carrying an actionable genotype in certain genes in the cardiovascular disease group and a reduced life span.ConclusionsOn the basis of the ACMG SF v3.0 guidelines, we found that approximately 1 in 25 Icelanders carried an actionable genotype and that carrying such a genotype was associated with a reduced life span. (Funded by deCODE Genetics-Amgen.).Copyright © 2023 Massachusetts Medical Society.

16 keywords...

hide…